Chemical Exchange Saturation Transfer (CEST) MRI for the Characterization Small Renal Masses

项目摘要 德克萨斯大学西南分校科学家和临床医生之间的学术-工业合作伙伴关系 （UTSW）医疗中心和飞利浦汉堡研究所以及飞利浦北美（Philips）已经成立 目的是将新的分子MR成像方法，化学交换饱和， 转移（CEST），成为评估小肾脏肿块（SRM）的临床工具。CEST已经 在神经肿瘤学应用中证明了可行性。供应商关系管理具有挑战性，因为 其中相当多的是良性或惰性恶性肿瘤，导致患者暴露于 活组织检查和手术造成的不必要的发病率。良性/惰性肿瘤之间的非侵入性区分 而侵袭性肿瘤将允许更好的风险分层和患者管理。虽然小说，CEST 已经被某些临床中心用于神经肿瘤学的评估。最近，我们集团 证明了CEST对乳腺病变定性的前景。在这里，我们建议扩大 通过解决CEST在肾肿瘤学中应用的固有挑战， 腹部和优化CEST在SRMs患者。 我们的假设是CEST-MRI的技术发展允许观察侵袭性肿瘤 SRM中的微环境。我们的目标是推进CEST方法，使其成为全面SRM的一部分 评估协议。该项目的目标将通过以下具体目标实现： 目的1：在3 T人体MRI系统上开发和优化SRMs的CEST方法。 这是技术发展目标，我们将评估解决主要问题的几种方法 与CEST向肾肿瘤学应用的转化相关：（i）改善的分辨率和脂肪分离， (ii)使用伪载波和欠采样算法的采集加速，（iii）运动校正，以及 (iv)先进的Z谱分析方法。 目的2：评价优化的CEST-MRI作为SRM组织学预测生物标志物的价值。 目的的重点是将CEST技术转化为SRM患者：（i）评价优化的 在一组SRM患者中：（ii）CEST-MRI测量与组织病理学结果的相关性， CEST-MRI与糖原沉积的相关性。

Project Summary An Academic-Industrial partnership between scientists and clinicians at the University of Texas Southwestern (UTSW) Medical Center and Philips Research Hamburg and Philips North America (Philips) has been formed with the purpose of translating the novel molecular MR imaging method, Chemical Exchange Saturation Transfer (CEST), into a clinical tool for the assessment of Small Renal Masses (SRMs). CEST has already demonstrated feasibility in neurooncology applications. The management of SRMs is challenging because a substantial number of them are benign or indolent malignant tumors, leading to patient exposure to unnecessary morbidity from biopsies and surgery. Non-invasive distinction between benign/indolent tumors and aggressive tumors would allow for better risk stratification and patient management. While novel, CEST has already been adopted by certain clinical centers for assessment in neuro oncology. Recently, our group demonstrated the promise of CEST to the characterization of breast lesions. Here, we propose to broaden the application of CEST to renal oncology by addressing the inherent challenges of application of CEST in the abdomen and by optimizing CEST in patients with SRMs. Our hypothesis is that technical development of CEST-MRI allows observation of aggressive tumor microenvironment in SRM. Our goal is to advance CEST methodology to become a part of comprehensive SRM evaluation protocol. The goals of the project will be achieved via the following Specific Aims: Aim 1: To develop and optimize CEST methodology for SRMs on 3T human MRI system. This is technical development Aim, where we will evaluate several approaches addressing major issues associated with translation of CEST to kidney oncology applications: (i) improved resolution and fat separation, (ii) acceleration of acquisition using pseudo-cartesian and undersampled algorithms,(iii) motion correction and (iv) advanced Z-spectrum analysis methods. Aim 2: To evaluate the optimized CEST-MRI as a predictive biomarker of SRM hystology. The Aim's focus in on the translation of the CEST technology to SRM patients: (i) evaluation of the optimized in a group of SRM patients: (ii) correlation of the CEST-MRI measurements with histopathology results and correlation of CEST-MRI with glycogen deposition.